TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma

BACKGROUND & AIMS: TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer immunotherapy in HCC is unknown. PD1 blockade is clinically effective in about 20% of advanced HCC patients. Here we aim to determine whether co-blockade of TIGIT/PD1 has added value to restore funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Zhouhong, Zhou, Guoying, Campos Carrascosa, Lucia, Gausvik, Erik, Boor, Patrick P.C., Noordam, Lisanne, Doukas, Michael, Polak, Wojciech G., Terkivatan, Türkan, Pan, Qiuwei, Takkenberg, R. Bart, Verheij, Joanne, Erdmann, Joris I., IJzermans, Jan N.M., Peppelenbosch, Maikel P., Kraan, Jaco, Kwekkeboom, Jaap, Sprengers, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255944/
https://www.ncbi.nlm.nih.gov/pubmed/33781741
http://dx.doi.org/10.1016/j.jcmgh.2021.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255944/
https://www.ncbi.nlm.nih.gov/pubmed/33781741
http://dx.doi.org/10.1016/j.jcmgh.2021.03.003

Ejemplares similares